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Germline mutations in the LKB1/STK11 gene cause
characteristic hamartomas and freckling to develop
in patients with Peutz–Jeghers syndrome (PJS). The
hamartomas arise as a result of somatic ‘‘second hits’’
at LKB1/STK11 and therefore contain a neoplastic
element. The origin of the pigmented lesions in PJS
is unknown and difficult to test, as these are hardly
ever biopsied. PJS patients are at increased risk of
benign and malignant tumors, particularly of the
colon, breast, pancreas, testis, and ovary, although the
increased risk for any one of these sites may be quite
modest. Somatic LKB1/STK11 mutations have been
found, albeit at a low frequency, in sporadic tumors
of the colon, stomach, ovary, and testis. Although PJS
patients are not known to have an excess of skin
tumors, if the freckles of PJS patients are actually
small, benign tumors, LKB1/STK11 mutations must
Germline mutations in the LKB1/STK11 gene (chro-mosome 19p13.3) cause Peutz–Jeghers syndrome(PJS, MIM175200) (Hemminki et al, 1998; Jenneet al, 1998). PJS has pathognemonic features ofmultiple gastrointestinal hamartomas, which have an
arborising structure and smooth muscle core, and melanin freckling,
which is usually present on the lips and inside the mouth, and may
also occur on the digits, palms, soles, and axillae (reviewed in
Tomlinson and Houlston, 1997). LKB1/STK11 acts as a tumor
suppressor gene in the hamartomas of PJS patients (Hemminki
et al, 1997).
PJS patients are at about 20-fold increased risk of benign and
malignant tumors, particularly of the colon, breast, pancreas, testis,
and ovary, although the increased risk for any one of these sites
may be quite modest (Tomlinson and Houlston, 1997). By analogy
with hamartoma predisposition genes such as PTEN and DPC4,
LKB1/STK11 is a good candidate for involvement in the pathogen-
esis of a spectrum of sporadic cancers. Mutations of LKB1/STK11
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provide these lesions with a selective advantage, and
similar mutations might also give a selective advantage
to related malignant tumors, such as melanomas. We
have therefore screened 16 melanoma cell lines, 15
primary melanomas, and 19 metastases for LKB1/
STK11 mutations. Two LKB1/STK11 mutations were
found: a missense change (Y49D) accompanied by
allele loss in a cell line; and a missense change (G135R),
without a detected mutation in the other allele, in a
primary tumor. Both these mutations are highly likely
to be pathogenic. Novel polymorphisms, including an
unusual heptanucleotide repeat, were also found in
introns 2 and 3. LKB1/STK11 mutations occur in a
significant minority of tumors of several sites, includ-
ing malignant melanomas. Key words: LKB1/STK11/
melanoma/Peutz-Jeghers. J Invest Dermatol 112:509–511,
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have been found in a significant minority of sporadic tumors of
the colon (Dong et al, 1998; Wang et al, 1998; Avizienyte et al,
1998), ovary (Wang et al, 1999), stomach (Park et al, 1998), and
testis (Avizienyte et al, 1998).
The origin of the pigmented lesions in PJS is essentially unknown.
It is generally supposed that they are simple lentigines, but this
theory does not explain why PJS freckles are relatively highly
pigmented or why they occur in areas that usually show no freckling
at all and/or have little light exposure. An alternative theory is that
the PJS freckles are actually benign neoplasms of melanocytes (or
some precursor), which have a very limited growth potential and
do not seem to increase in size throughout life (Tomlinson and
Bodmer, 1996); indeed, PJS pigmentation often fades in middle
age. This theory is extremely difficult to test, because PJS freckles
are hardly ever biopsied, but is consistent with data showing that
PJS pigmentation can occur in proliferative lesions such as psoriatic
plaques (Banse-Kupin et al, 1986).
There are no reports of any PJS freckle becoming malignant,
but if the freckles of PJS patients are actually small, benign tumors,
LKB1/STK11 mutations must provide these lesions with a selective
advantage. Although PJS patients are not known to be at increased
risk of skin tumors (Boardman et al, 1998), it is theoretically possible
that LKB1/STK11 mutations provide a selective advantage to
malignant lesions that are related to PJS freckles, e.g., malignant
melanoma. There are few, if any, reports of allele loss (LOH) close
to the LKB1/STK11 locus on 19p13.3 in melanoma, but this may
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reflect an absence of studies in this region and translocation
breakpoints have been observed in melanomas in this region
(Parmiter et al, 1986). Below, we report the results of screening 16
melanoma cell lines, 15 primary melanomas, and 19 metastases for
somatic LKB1/STK11 mutations.
Figure 1. Y49D LKB1/STK11 mutation in melanoma cell line
WDS3. The mutation is arrowed in the tumor sample (above). Note the
absence of the underlying wild-type (T) allele in the tumor, compared
with the normal sequence (below).
Figure 2. G135R LKB1/STK11 mutation in primary tumor S1. (a) Single strand conformational polymorphism analysis of tumor (S1) for exon 3
(lane S1); tumors without exon 3 mutations are shown in the other lanes of the gel. Note the additional bands in lanes S2, S6, and S7, which result from
the C/G SNP polymorphism at positions 149 and 150 in intron 3. (b) Sequence of the mutation (arrowed). Note that the mutant allele (C) in tumor A
is weaker than the wild type (G). This probably results from the presence of a small amount of contaminating normal tissue in the tumor specimen. This
mutation is repeatedly detectable and inspection of the surrounding sequence shows no spurious peaks masquerading as missense changes. The change in
tumor A does not affect a restriction site and the mutatution cannot, therefore, be confirmed using this method. The wild-type sequence is shown in (c).
MATERIALS AND METHODS
Melanoma tissue was derived from either cells (16 cell lines), fresh-frozen
tumors (19 metastases), or microdissected, paraffin-embedded, archival
material (14 primary tumors and one metastasis). None of these cases had
known clinical or familial features suggestive of PJS, consistent with the
fact that melanoma is not a tumor associated with PJS. DNA was extracted
from each of the tumors to be studied using the Qiagen Tissue Extraction
Kit. Standard clinicopathologic data (patient age, tumor grade, and stage)
were available from hospital records.
Single strand conformational polymorphism analysis was performed on
the tumor samples in order to screen for mutations in the coding
regions and flanking intronic sequences of LKB1/STK11. Published
oligonucleotides and reaction conditions (Wang et al, 1998) were used for
exon-by-exon amplification of LKB1/STK11 in the polymerase chain
reaction. Polymerase chain reaction products were heated to 90°C for
5 min and subjected to electrophoresis on a 12.5% precast acrylamide gel
under denaturing conditions using the Phast System (Pharmacia, Uppsala,
Sweden). DNA was detected by silver-staining of gels using the standard
Phast System protocol. For all tumors with possible mutations according
to single strand conformational polymorphism analysis, that exon was
reamplified from genomic DNA in the polymerase chain reaction and
purified polymerase chain reaction products were sequenced in forward
and reverse orientation using the ABI Ready Reaction Dye Terminator
Cycle Sequencing kit and the 377 Prism sequencer. All sequencing
reactions were performed in duplicate and alongside samples with wild-
type genotypes and patient samples with known germline mutations in
LKB1/STK11.
RESULTS AND DISCUSSION
We found a mutation of LKB1/STK11 in two of 50 (4%)
melanomas studied. One of these tumors was a cell line derived
from a primary lesion and the other was from a primary
melanoma; in neither case was constitutional DNA available for
analysis. Both mutations are novel missense variants (Figs 1, 2).
In the cell line, Tyr is substituted for Asp at codon 49. In the
primary lesion, Arg is substituted for Gly at codon 135. Both
changes are highly likely to have pathogenic effects, because: (i)
the amino acid changes are nonconservative, substituting a
charged for an uncharged residue; (ii) no polymorphism at either
site has been reported previously by any group; (iii) the mutations
lie at the start of or within the kinase core of the LKB1/
STK11 protein (Hemminki et al, 1998); (iv) both the amino
acids concerned are conserved between human, mouse, and
Xenopus and lie within conserved motifs (http://www.ncbi.
nlm.nih.gov/htbin-post/Entrez/query?uid53024672&form5
6&db5p&Dopt5f; http://www.ncbi.nlm.nih.gov/htbin-post/
Entrez/query?uid53024670&form56&db5p&Dopt5f; Churchman
et al unpublished data); (v) we have found no germline variant
at either site in over 150 patients with tumors and over
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50 normal individuals screened previously; and (vi) in the case
of the cell line, no wild-type LKB1/STK11 allele was detected
on sequencing (Fig 1), strongly suggesting mutation of the other
allele by loss of heterozygosity. No ‘‘second hit’’ was found in
the melanoma with the G135R mutation, but the action of
LKB1/STK11 as a tumor suppressor (Hemminki et al, 1997;
Park et al, 1998) strongly suggests that a second mutation (or
an alternative such as promoter methylation) had occurred in
this tumor.
Three novel polymorphisms were detected in introns 2 and
3 of LKB1/STK11. These comprise an A/G single nucleotide
polymorphism (SNP) at the –49 position in intron 2; G/C SNP
at both 149 and 150 of intron 3; and an unusual heptanucleotide
repeat (with alleles of two and three repeat units) at 130 of
intron 3. In addition, a previously described common missense
polymorphism was detected in intron 7 (Wang et al, 1998).
Formal assessment of allele frequencies at each site was not
undertaken. Combined use of these polymorphic sites may be
useful for further studies of LKB1/STK11.
Although our method is sensitive enough to detect common
missense polymorphisms (see above), it is unlikely that single
strand conformational polymorphism has 100% sensitivity for point
mutations. Moreover, we have not searched for large-scale deletions
of LKB1/STK11 or for promoter methylation. The involvement
of LKB1/STK11 in melanoma pathogenesis may therefore exceed
4% of tumors.
The accumulated evidence suggests that LKB1/STK11 mutations
are involved in the pathogenesis of a small but potentially signific-
ant minority of sporadic malignant melanomas, in addition to
cancers of the stomach, ovary, and testis. Neither of the tumors
with LKB1/STK11 mutations in our study had exceptional clinical
features. The frequency of LKB1/STK11 mutations in colon cancer
is probably similarly low (Wang et al, 1998; Avizienyte et al 1998),
although one report suggests that mutations occur in as many as
54% of left-sided colon cancers (Dong et al, 1998). The mutations
in most of the tumor types are too rare for any associations between
the molecular and clinicopathologic data to be detected. LKB1/
STK11 appears to act as a tumor suppressor in sporadic tumors, as
it does in the hamartomas in PJS (Hemminki et al, 1997). It is
noteworthy that the majority of somatic LKB1/STK11 mutations
in sporadic tumors are missense changes (Dong et al, 1998;
Avizienyte et al, 1998; Park et al, 1998), suggesting that abolition
of kinase function is not required to provide tumors with a selective
advantage. By contrast, most, although not all, germline LKB1/
STK11 mutations lead to a truncated protein (Hemminki et al,
1998; Jenne et al, 1998; Nakagawa et al, 1998).
The question remains of whether or not the characteristic freckles
of PJS patients are (clonal) neoplasms. This hypothesis can be
proved by finding allele loss or other somatic LKB1/STK11
mutations in the freckles themselves, but none of over 100 PJS
patients that we have studied has ever had a freckle biopsied. We
have analyzed a biopsied oral freckle from a patient with typical
PJS freckling, but no known gastrointestinal hamartomas, and have
found no evidence for LKB1/STK11 mutations.
One of the unexplained phenomena in Mendelian cancer syn-
dromes is the site specificity of cancers caused by mutations in
genes with apparent ‘‘housekeeping’’ roles. One particular aspect
of this problem is that germline mutations in cancer-predisposing
genes often produce a very different tumor spectrum from the
spectrum of tumors that carry somatic mutations in the same genes.
Unusually, the spectrum of cancers in the inherited syndrome of
PJS seems to be as broad as the spectrum of sporadic cancers that
have somatic mutations in LKB1/STK11. The combined data on
LKB1/STK11 mutations in sporadic tumors accords with the
relatively low excess site-specific risk of cancer that is found in PJS
patients. The relatively infrequent occurrence of LKB1/STK11
mutations in sporadic tumors also suggests some genetic redundancy
in the pathways of tumorigenesis, but the large variety of inherited
and sporadic tumors with LKB1/STK11 mutations suggests a
widespread role for normal LKB1/STK11 in areas such as pre-
venting tumor growth.
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